SSY GROUP(02005): Metoclopramide and Metoclopramide Hydrochloride have been approved and registered by the National Medical Products Administration as active pharmaceutical ingredients for use in marketed formulations.

12:09 27/02/2026

Shi Si Pharmaceutical Group (02005) announced that its metoclopramide and metoclopramide hydrochloride have been approved and registered by the China Food and Drug Administration as active pharmaceutical ingredients for use in marketed formulations.

SSY GROUP (02005) announced that the methoxychloropromazine and methoxychloropromazine hydrochloride of this group have been approved by the China National Medical Products Administration for registration as active pharmaceutical ingredients for use in marketed formulations. Both active pharmaceutical ingredients belong to dopamine receptor D2 antagonists and also have 5-hydroxytryptamine 4 (5-HT4) receptor agonist effects, promoting gastrointestinal motility. They are mainly used for antiemetic and treatment of nausea, belching, stomach bloating, and gastroesophageal reflux disease.

SITOY GROUP(01023) will distribute a mid-term dividend of HK$0.02 per share on April 27th.

CEB WATER (01857) will distribute a final dividend of HK$0.0422 per share on May 22nd.

On February 26th, ZTO Express-W (02057) invested 14.8037 million US dollars to repurchase 617,800 shares.

SITOY GROUP(01023) will distribute a mid-term dividend of HK$0.02 per share on April 27th.

CEB WATER (01857) will distribute a final dividend of HK$0.0422 per share on May 22nd.

On February 26th, ZTO Express-W (02057) invested 14.8037 million US dollars to repurchase 617,800 shares.